# Embecta Corp.: overview

EMBC · Nasdaq · CIK 1872789 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/embc.md) · [Financials](/companies/embc/financials.md) · [Filings](/companies/embc/filings.md) · [Insiders](/companies/embc/insiders.md)

Latest reported revenue: [$271.7m](/filings/0001872789-26-000033.md) for Q3 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001872789-26-000033).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [286 d](/filings/0001872789-25-000036.md) | [262](/filings/0001872789-26-000009.md) | [259](/filings/0001872789-26-000017.md) | [296](/filings/0001872789-26-000033.md) | [264 d](/filings/0001872789-25-000036.md) | [261](/filings/0001872789-26-000009.md) | [222](/filings/0001872789-26-000017.md) | [272](/filings/0001872789-26-000033.md) |
| Gross margin | % | [60.7% d](/filings/0001872789-25-000036.md) | [60.0%](/filings/0001872789-26-000009.md) | [63.4%](/filings/0001872789-26-000017.md) | [66.7%](/filings/0001872789-26-000033.md) | [60.0% d](/filings/0001872789-25-000036.md) | [61.9%](/filings/0001872789-26-000009.md) | [57.6%](/filings/0001872789-26-000017.md) | [56.4%](/filings/0001872789-26-000033.md) |
| Operating margin | % | [9.2% d](/filings/0001872789-25-000036.md) | [11.0%](/filings/0001872789-26-000009.md) | [24.3%](/filings/0001872789-26-000017.md) | [31.8%](/filings/0001872789-26-000033.md) | [21.4% d](/filings/0001872789-25-000036.md) | [31.9%](/filings/0001872789-26-000009.md) | [15.8%](/filings/0001872789-26-000017.md) | [17.9%](/filings/0001872789-26-000033.md) |
| Net margin | % | [5.1% d](/filings/0001872789-25-000036.md) | [0.0%](/filings/0001872789-26-000009.md) | [9.1%](/filings/0001872789-26-000017.md) | [15.4%](/filings/0001872789-26-000033.md) | [10.0% d](/filings/0001872789-25-000036.md) | [16.9%](/filings/0001872789-26-000009.md) | [(1.8%)](/filings/0001872789-26-000017.md) | [7.8%](/filings/0001872789-26-000033.md) |
| Diluted EPS | $ per share | not reported | [0.00](/filings/0001872789-26-000009.md) | [0.40](/filings/0001872789-26-000017.md) | [0.78](/filings/0001872789-26-000033.md) | not reported | [0.74](/filings/0001872789-26-000009.md) | [(0.07)](/filings/0001872789-26-000017.md) | [0.36](/filings/0001872789-26-000033.md) |
| Free cash flow | $m | [26.6 d](/filings/0001872789-25-000036.md) | [(6.8)](/filings/0001872789-26-000009.md) | [31.7 d](/filings/0001872789-26-000017.md) | [80.8 d](/filings/0001872789-26-000033.md) | [76.7 d](/filings/0001872789-25-000036.md) | [16.6](/filings/0001872789-26-000009.md) | [30.6 d](/filings/0001872789-26-000017.md) | [40.7 d](/filings/0001872789-26-000033.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY (2021-09-30) | FY2022 (2022-09-30) | FY2023 (2023-09-30) | FY2024 (2024-09-30) | FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,165](/filings/0001872789-23-000031.md) | [1,130](/filings/0001872789-24-000037.md) | [1,121](/filings/0001872789-25-000036.md) | [1,123](/filings/0001872789-25-000036.md) | [1,080](/filings/0001872789-25-000036.md) |
| Gross margin | % | [68.7%](/filings/0001872789-23-000031.md) | [68.6%](/filings/0001872789-24-000037.md) | [66.9%](/filings/0001872789-25-000036.md) | [65.5%](/filings/0001872789-25-000036.md) | [62.6%](/filings/0001872789-25-000036.md) |
| Operating margin | % | [42.2%](/filings/0001872789-23-000031.md) | [27.4%](/filings/0001872789-24-000037.md) | [19.8%](/filings/0001872789-25-000036.md) | [14.9%](/filings/0001872789-25-000036.md) | [22.4%](/filings/0001872789-25-000036.md) |
| Net margin | % | [35.6%](/filings/0001872789-23-000031.md) | [19.8%](/filings/0001872789-24-000037.md) | [6.3%](/filings/0001872789-25-000036.md) | [7.0%](/filings/0001872789-25-000036.md) | [8.8%](/filings/0001872789-25-000036.md) |
| Diluted EPS | $ per share | [7.28](/filings/0001872789-23-000031.md) | [3.89](/filings/0001872789-24-000037.md) | [1.22](/filings/0001872789-25-000036.md) | [1.34](/filings/0001872789-25-000036.md) | [1.62](/filings/0001872789-25-000036.md) |
| Free cash flow | $m | [420](/filings/0001872789-23-000031.md) | [389](/filings/0001872789-24-000037.md) | [41.2](/filings/0001872789-25-000036.md) | [19.9](/filings/0001872789-25-000036.md) | [182](/filings/0001872789-25-000036.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/embc/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $15.0m | 4,599,771 |  | Reduced −4,567,441 |
| [YACKTMAN ASSET MANAGEMENT LP](/funds/905567.md) | 2026-06-30 | $14.1m | 4,315,952 |  | Added +644,075 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $8.3m | 2,557,148 |  | Reduced −6,803 |
| [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $8.3m | 2,534,961 |  | Unchanged |
| [Jefferies Financial Group Inc.](/funds/96223.md) | 2026-06-30 | $7.7m | 2,355,117 |  | Reduced −45 |
| [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $6.6m | 2,038,731 |  | Added +1,239,043 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $6.5m | 1,996,747 |  | Added +1,386,943 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $5.3m | 1,610,666 |  | Reduced −935,307 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $5.2m | 1,594,457 |  | Added +128,810 |
| [BRIGADE CAPITAL MANAGEMENT, LP](/funds/1421306.md) | 2026-06-30 | $4.9m | 1,516,453 |  | New +1,516,453 |

## Recent filings

[All 254 filings](/companies/embc/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-07 | 14:28 ET | [10-Q](/filings/0001872789-26-000033.md) | Quarterly report, period 2026-06-30 | 0001872789-26-000033 |
| 2026-08-07 | 07:07 ET | [8-K](/filings/0001872789-26-000029.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001872789-26-000029 |
| 2026-07-31 | 16:35 ET | [8-K/A](/filings/0001872789-26-000026.md) | 9.01 Financial statements and exhibits | 0001872789-26-000026 |
| 2026-05-15 | 09:15 ET | [8-K](/filings/0000947871-26-000546.md) | 2.01 Completion of an acquisition or disposition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000947871-26-000546 |
| 2026-05-05 | 13:31 ET | [10-Q](/filings/0001872789-26-000017.md) | Quarterly report, period 2026-03-31 | 0001872789-26-000017 |
| 2026-05-05 | 06:55 ET | [8-K](/filings/0001872789-26-000014.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001872789-26-000014 |
| 2026-03-20 | 20:00 ET | [8-K](/filings/0000947871-26-000310.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000947871-26-000310 |
| 2026-02-13 | 17:25 ET | [8-K](/filings/0000947871-26-000153.md) | 5.07 Shareholder vote results | 0000947871-26-000153 |
| 2026-02-05 | 11:26 ET | [10-Q](/filings/0001872789-26-000009.md) | Quarterly report, period 2025-12-31 | 0001872789-26-000009 |
| 2026-02-05 | 06:54 ET | [8-K](/filings/0001872789-26-000005.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001872789-26-000005 |

## Latest annual report

[Form 10-K for the fiscal year ended Sep 30, 2025](/filings/0001872789-25-000036.md), filed Nov 25, 2025.

## Forecast league

Q4 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/989584e2-0eac-44aa-8611-7168dc53388a)

## About the filer

- CIK: 1872789
- Tickers: EMBC
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.